Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. / Ritzén, Andreas; Mathiesen, Jesper Mosolff; Thomsen, Christian.

In: Basic and Clinical Pharmacology and Toxicology, Vol. 97, No. 4, 01.10.2005, p. 202-213.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ritzén, A, Mathiesen, JM & Thomsen, C 2005, 'Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators', Basic and Clinical Pharmacology and Toxicology, vol. 97, no. 4, pp. 202-213. https://doi.org/10.1111/j.1742-7843.2005.pto_156.x

APA

Ritzén, A., Mathiesen, J. M., & Thomsen, C. (2005). Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic and Clinical Pharmacology and Toxicology, 97(4), 202-213. https://doi.org/10.1111/j.1742-7843.2005.pto_156.x

Vancouver

Ritzén A, Mathiesen JM, Thomsen C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic and Clinical Pharmacology and Toxicology. 2005 Oct 1;97(4):202-213. https://doi.org/10.1111/j.1742-7843.2005.pto_156.x

Author

Ritzén, Andreas ; Mathiesen, Jesper Mosolff ; Thomsen, Christian. / Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. In: Basic and Clinical Pharmacology and Toxicology. 2005 ; Vol. 97, No. 4. pp. 202-213.

Bibtex

@article{9d4da19609c6466cab97f6e8c0c67c18,
title = "Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators",
abstract = "The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.",
author = "Andreas Ritz{\'e}n and Mathiesen, {Jesper Mosolff} and Christian Thomsen",
year = "2005",
month = oct,
day = "1",
doi = "10.1111/j.1742-7843.2005.pto_156.x",
language = "English",
volume = "97",
pages = "202--213",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators

AU - Ritzén, Andreas

AU - Mathiesen, Jesper Mosolff

AU - Thomsen, Christian

PY - 2005/10/1

Y1 - 2005/10/1

N2 - The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.

AB - The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.

UR - http://www.scopus.com/inward/record.url?scp=26444616159&partnerID=8YFLogxK

U2 - 10.1111/j.1742-7843.2005.pto_156.x

DO - 10.1111/j.1742-7843.2005.pto_156.x

M3 - Journal article

C2 - 16176554

AN - SCOPUS:26444616159

VL - 97

SP - 202

EP - 213

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 4

ER -

ID: 221756457